Aim To provide evidence regarding the effectiveness of aripiprazole in improving penile erection with a therapeutic strategy of add-on or switching therapy in patients with schizophrenia. Methods PubMed, Cochrane, Clinical Key, ProQuest, EBSCOhost, and ScienceDirect were searched for any design study that evaluated aripiprazole only or versus control (placebo or other antipsychotic) for erectile dysfunction in patients with schizophrenia. Three studies were identified and analysed from 295 initial articles. Data were then extracted from the studies and summarized descriptively. Results Two hundred ninety-five articles were screened, and three studies were identified and eventually selected. After the add-on or switching antipsychotic therapy to aripiprazole, the prevalence of erectile dysfunction and the score of erectile dysfunction or penile erection assessed by Nagoya and Sexual Function Questionnaire (NSFQ) and Arizona Sexual Experience Scale (ASEX) decreased. Conclusion Aripiprazole was effective to improve penile erectile function in patients with schizophrenia. The therapeutic strategy is adjunctive treatment or switching therapy to aripiprazole.
Khan A, Nawaz H, Nazneen Z, Yousafzai A. Antipsychotics induced sexual dysfunction. Pakistan J Physiol. 2017;3–7.
2.
Banerjee A, Chitnis U, Jadhav S, Bhawalkar J, Chaudhury S. Hypothesis testing, type I and type II errors. Ind Psychiatry J. 2009;127–31.
3.
Saleem M, Martin H, Coates P. Prolactin biology and laboratory measurement: an update on physiology and current analytical issues. Clin Biochem Rev. 2018;3–16.
4.
Peter F, Timothy G. Prolactin and dopamine: what is the connection? a review article. J Psychopharmacol. 2008;12–9.
5.
Kevan, Ian. Handbook of Sexual Dysfunction. 2005;155–91.
6.
Tsertsvadze A, Fink H, Yazdi F, Macdonald R, Bella A. Clinical guidelines annals of internal medicine oral phosphodiesterase-5 inhibitors and hormonal treatments. Ann Intern Med. 2009;650–61.
7.
Mcgahuey C, Gelenberg A, Laukes C, Moreno F, Delgado P, Mcknight K. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;25–38.
8.
Kikuchi T, Iwamoto K, Sasada K, Aleksis B, Yoshida K, Ozaki N. Reliability and validity of a new sexual function questionnaire (Nagoya Sexual Function Questionnaire) for schizophrenic patients taking antipsychotics. Hum Psychopharmacol. 2011;300–6.
9.
Raghuthaman G, Venkateswaran R, Krishnadas R. Adjunctive aripiprazole in risperidone-induced hyperprolactinemia: a double-blind, randomized, placebo-controlled trial. Br J Psych Open. 2015;172–7.
10.
Jeong H, Lee M, Lee H, Ko Y, Han C, Joe S. Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study. Int Clin Psychopharmacol. 2012;177–83.
11.
Fujioi J, Iwamoto K, Banno M, Kikuchi T, Aleksic B, Ozaki N. Effect of adjunctive aripiprazole on sexual dysfunction in schizophrenia: a preliminary open-label study. Pharmacopsychiatry. 2017;74–8.
12.
Byron C Wallace J, Kuiper A, Sharma M, Zhu I. Extracting PICO Sentences from Clinical Trial Reports using Supervised Distant Supervision. J Mach Learn Res. 2016;90–8.
13.
Liberati A, Altman D, Tetzlaff J, Mulrow C, Gøtzsche P, Ioannidis J. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;56–62.
14.
Owen M, Sawa A, Mortensen P, Schizophrenia. Lancet. 2016;86–97.
15.
Hanssens L, ’italien L, Loze G, Marcus J, Pans R, Kerselaers M, et al. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry. 2008;(8):95.
16.
Mir A, Shivakumar K, Williamson R, Mcallister V, ’keane O, Aitchison V, et al. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol. 2008;244–53.
17.
Tuplin E, Holahan M. Aripiprazole, a drug that displays partial agonism and functional selectivity. Curr Neuropharmacol. 2017;1192–207.
18.
Mahmoud A, Hayhurst K, Drake R, Lewis S. Second generation antipsychotics improve sexual dysfunction in schizophrenia: a randomized controlled trial. Schizophr Res Treatment. 2011;
19.
Hanssens L, ’italien L, Loze G, Marcus J, Pans R, Kerselaers M, et al. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry. 2008;1–11.
20.
Chisholm-Burns M, Wells B, Schwinghammer T, Malone P, Kolesar J, Dipiro J. Pharmacotherapy: Principles & Practice. 2016;(4).
21.
Anthony J, Rany S. Psychotropics and sexual dysfunction. Cent European J Urol. 2013;466–71.
22.
Yeon W, Yooseok K, Jun H. Antipsychotic induced sexual dysfunction and its management. World J Mens Health. 2012;153–9.
23.
Miyamoto B, Galecki M, Francois D. Guidelines for antipsychotic-induced hyperprolactinemia. Psychiatr Ann. 2015;266–72.
24.
Indonesian Ministry of Health. Hasil utama riset kesehatan dasar (RISKESDAS) (Main result of basic health data) [In Indonesian]. 2018;
25.
Meyer N, Maccabe J. Schizophrenia Med (United Kingdom). 2016;649–53.
26.
Fatani B, Aldawod R, Alhawaj F. Schizophrenia: etiology, pathophysiology, and management : a review. Egypt J Hosp Med. 2017;2640–6.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
